Intranasal Delivery of Lipid Nanoparticles: A Ground-breaking Approach for Brain Targeting

被引：0
作者：
Jena D. [1 ]
Srivastava N. [1 ]
Yasir M. [2 ]
Dan D. [1 ]
机构：
[1] Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector 125, Noida
[2] Department of Pharmacy (Pharmaceutics), College of Health Sciences, Arsi University, Asella
来源：
Current Nanomaterials | 2024年 / 9卷 / 03期
关键词：
blood-brain barrier; blood-cerebrospinal fluid; brain; FDA-approved formulation; lipid nanoparticles; Nasal cavity; nose-to-brain patch;
D O I：
10.2174/2405461508666230804103023
中图分类号：
学科分类号：
摘要：
In the present scenario, various novel delivery systems are available for drug delivery to systemic circulation. So, to accomplish a greater therapeutic effect, the nature of the drug delivery is very important. This delivery is one of the innovative approaches where the drug is targeted to the brain through the nasal cavity. As we know, the human brain is the most crucial part of the body that controls various functions of our system. So, safely reaching the targeted site of the brain is necessary to achieve brain specificity. This delivery system helps us to tackle the problems that may arise in the other delivery system and helps the drug reach the brain without any difficulties. The major obstacles we faced during this delivery were the blood-brain barrier (BBB) and the brain-cerebrospinal fluid barrier. So, if we target the drug to the brain, then we have to overcome these challenges, and before that, we must have a clear understanding of the targeted site and the mechanism behind the drug tar-geting. Advancements in science and technology have helped discover many recent strategies and formulations available for intranasal delivery. The development of lipid nanoparticles is one of the primitive approaches for targeting any type of drug(hydrophilic/lipophilic) in the brain. So, the aim of this review mainly focused on the mechanism of intranasal delivery, the devices used, and some recent strategies like the development of lipid nanoparticles, surface-modified lipid nanocarriers, and nose-to-brain patches. This review article also includes a few FDA-approved formulations for nose-to-brain delivery and their regulatory aspects related to clinical trials and future perspectives. © 2024 Bentham Science Publishers.
引用
收藏
页码：209 / 223
页数：14
相关论文
共 92 条
[51]  
Salade L, Wauthoz N, Vermeersch M, Amighi K, Goole J., Chi-tosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery, Eur J Pharm Biopharm, 129, pp. 257-266, (2018)
[52]  
Wingrove J, Swedrowska M, Scherliess R, Et al., Characterisation of nasal devices for delivery of insulin to the brain and evaluation in humans using functional magnetic resonance imaging, J Control Release, 302, pp. 140-147, (2019)
[53]  
Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J., Insights into direct nose to brain delivery: Current status and future perspective, Drug Deliv, 21, 2, pp. 75-86, (2014)
[54]  
Pandey M, Choudhury H, Verma RK, Et al., Nanoparticles based intranasal delivery of drug to treat Alzheimer’s disease: A recent update, CNS Neurol Disord, 19, 9, pp. 648-662, (2020)
[55]  
Patel AA, Patel RJ, Patel SR., Nanomedicine for intranasal delivery to improve brain uptake, Curr Drug Deliv, 15, 4, pp. 461-469, (2018)
[56]  
Lai F, Fadda AM, Sinico C., Liposomes for brain delivery, Expert Opin Drug Deliv, 10, 7, pp. 1003-1022, (2013)
[57]  
Hong SS, Oh KT, Choi HG, Lim SJ., Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives, Pharmaceutics, 11, 10, (2019)
[58]  
Salade L, Wauthoz N, Deleu M, Et al., Development of coated liposomes loaded with ghrelin for nose-to-brain delivery for the treatment of cachexia, Int J Nanomedicine, 12, pp. 8531-8543, (2017)
[59]  
Hussain G, Zhang L, Rasul A, Et al., Role of plant-derived flavo-noids and their mechanism in attenuation of Alzheimer’s and Par-kinson’s diseases: An update of recent data, Molecules, 23, 4, (2018)
[60]  
Xu J, Tao J, Wang J., Design and application in delivery system of intranasal antidepressants, Front Bioeng Biotechnol, 8, (2020)
12345678910